Lenox Wealth Advisors Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Lenox Wealth Advisors reduced its stake in Pfizer by 5.39% during the most recent quarter end. The investment management company now holds a total of 16,118 shares of Pfizer which is valued at $523,835 after selling 918 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Apr 11, 2016.Pfizer makes up approximately 0.15% of Lenox Wealth Advisors’s portfolio.

Pfizer closed down -0.15 points or -0.46% at $32.5 with 3,52,74,322 shares getting traded on Friday. Post opening the session at $32.65, the shares hit an intraday low of $32.3 and an intraday high of $32.785 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

Other Hedge Funds, Including , Stillwater Capital Advisors reduced its stake in PFE by selling 1,859 shares or 0.49% in the most recent quarter. The Hedge Fund company now holds 374,359 shares of PFE which is valued at $12,166,668. Pfizer makes up approx 3.53% of Stillwater Capital Advisors’s portfolio.Rathbone Brothers Plc boosted its stake in PFE in the latest quarter, The investment management firm added 571,337 additional shares and now holds a total of 892,929 shares of Pfizer which is valued at $28,475,506. Pfizer makes up approx 1.75% of Rathbone Brothers Plc’s portfolio.Berson Corrado Investment Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 1,000 additional shares and now holds a total of 35,234 shares of Pfizer which is valued at $1,123,612. Pfizer makes up approx 0.70% of Berson Corrado Investment Advisors’s portfolio.Beacon Financial Group reduced its stake in PFE by selling 372 shares or 2.22% in the most recent quarter. The Hedge Fund company now holds 16,407 shares of PFE which is valued at $492,866. Pfizer makes up approx 0.11% of Beacon Financial Group’s portfolio.

On the company’s financial health, Pfizer reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Feb 2, 2016. Analyst had a consensus of $0.36. The company had revenue of $14047.00 million for the quarter, compared to analysts expectations of $13595.19 million. The company’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.

Many Wall Street Analysts have commented on Pfizer. JP Morgan Resumed Pfizer on Apr 7, 2016 to “Overweight”, Price Target of the shares are set at $38.Morgan Stanley Resumed Pfizer on Apr 7, 2016 to “Equal-Weight”, Price Target of the shares are set at $35.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.